Psychedelic Stocks

Hamilton Morris Confirmed as Keynote Speaker at Convergence Psychedelic Conference

Convergence, the biggest psychedelic culture and business conference in California, recently announced that Hamilton Morris would be a keynote speaker at the conference. Morris is a well-known advocate in the psychedelics space. In addition to being a scientific researcher, a journalist and a filmmaker, he has a television show known as “Hamilton’s Pharmacopeia.

The show, which runs on Vice TV, allows him to bring life to stories and experiences of psychedelics along with the uses of these substances and their cultural significance and the chemistry behind them.

At the moment, Morris is a consultant at Compass Pathway’s Discover Center, which is based at Philadelphia’s University of the Sciences. There, he advises the company on research related to new psychedelic compounds that can be developed into treatments for unmet mental health needs.

Psychedelics Today CEO and cofounder, Joe Moore, stated that Morris was a good academic and cultural fit for the conference, noting that his views on ending the drug war, cognitive liberty and evidence-based policy, aligned with Psychedelics Today’s values. Psychedelics Today is a leader in psychedelic storytelling, media, education and events. The organization will be holding the conference, which will include a curated agenda with more than 60 expert speakers in research, advocacy, culture and business.

Announced speakers include Dr. Carl Hart; Steve DeAngelo, an activist, author and trailblazing marijuana entrepreneur; Ezekiel Golan, an activist and scientist; and Laura Dawn, a psychedelic retreat facilitator, plant medicine integration guide and host of “The Psychedelic Leadership Podcast.

Additional speakers include the owner of Doorway Therapeutic Services, Courtney Watson, who is also a therapist; Zac Kamenetz, a community leader, rabbi and founder of Shefa Jewish Psychedelic Support; and managing director of PsychedeLiA Integration, Paul Antico.

Doorway Therapeutic Services is a therapy practice that addresses the mental health needs of Black, Indigenous and individuals of color as well as the LGBTQIA community.

The conference is set to run Oct. 20–23, 2022, in Los Angeles. Morris’ keynote will be held on the last day of the conference.

The conference’s full schedule will be released in the coming weeks as more speakers are announced. The event programming is holistic, with panels on research, ethics, business, veterans, therapeutic modalities/medical applications, policy, community, spirituality, Indigenous and diversity and inclusion.

Convergence will also include a concert series to celebrate individuals taking part in the modern psychedelic resurgence and the progress made thus far.

Visit psychedelicstoday.com/convergence to learn more about Convergence and see any updates.

Such conferences are a good facilitator of the proper flow of information between industry actors such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) and the general public, which appears to be hungrier than ever for science-backed information about the potential and risks associated with different psychedelic compounds.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

4 days ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

1 week ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’

NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multibillion-dollar unmet needs in central…

4 weeks ago

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of…

4 weeks ago